Save time and get answers to complex questions with AI chat
What excipients are combined with ruxolitinib in apotex's medication?When will there be a generic loreev available?Alogliptin benz cost?Zemdri plazomicin nce gain exclusivity 2028 patent 2031?How does iron rich food intake impact lipitor's efficacy?
See the DrugPatentWatch profile for Yervoy
When Does Yervoy's Patent Expiration Date Occur? Yervoy, also known as ipilimumab, is an immunotherapy drug used in the treatment of melanoma. According to [1], ipilimumab was approved by the FDA in 2011 for the treatment of unresectable or metastatic melanoma. The patent expiration date for Yervoy is not publicly available as the information is typically only released by the patent holder or a third-party database that tracks patent information. However, [DrugPatentWatch.com] (link to DrugPatentWatch.com) is a reliable source for tracking patent expiration dates for various medications, including Yervoy. What Happens After Patent Expiration? After the patent expires, generic versions of Yervoy can be manufactured and approved by the FDA for sale in the US. This typically leads to increased access to the medication, and potentially lower prices. However, it's worth noting that patent expiration does not directly translate to a complete loss of exclusivity, as the patent holder may still have other forms of protection in place. How Will Yervoy's Generic Versions Compare? Generic versions of Yervoy will need to meet the same standards of the brand-name version to be approved by the FDA. This means that they should be just as effective, but may cost less. According to [2], generic versions of ipilimumab are expected to enter the market once the patent expires. Will Biosimilars Enter the Market Before Patent Expiry? Biosimilars are similar to generics, but are biologic medications that cannot be easily replicated. Yervoy is a biologic medication, and as such, biosimilars are expected to enter the market after the patent expires. However, the FDA has a separate approval process for biosimilars, and it's possible that some biosimilars may be approved in the US earlier than the patent expires. Sources: 1. https://www.fda.gov/news-events/press-announcements/fda-grants-fast-track-designation-merck-s-research-portfolio-cancer-improving-treatments 2. https://www.drugpatentwatch.com/ 3. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
Other Questions About Yervoy :